Lupin launches Levothyroxine Sodium Tablets

22 Mar 2019 Evaluate

Lupin has launched Levothyroxine Sodium Tablets USP, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Levothyroxine Sodium Tablets USP, is the generic equivalent of AbbVie, Inc’s Synthroid Tablets. It is indicated for Hypothyroidism and Pituitary Thyrotropin Suppression.

Levothyroxine Sodium Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg had an annual sales of approximately $2.5 billion in US (IQVIA MAT January 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2113.40 -25.25 (-1.18%)
02-Feb-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1613.85
Dr. Reddys Lab 1190.50
Cipla 1309.40
Zydus Lifesciences 875.45
Lupin 2113.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×